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bine this approach with
GPU-accelerated molecu-
lar dynamics, new im-
plicit solvent models,
and recent improvements
in force fields. The initial
results of this protocol are
encouraging and we are
able to successfully refine
several difficult CASP9
refinement targets.3146-Pos Board B7
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Proteins are the building blocks of cells and the executioners of nearly all cel-
lular functions. Their activity directly depends on their specific three dimen-
sional structure, determined by the folding of its amino acid chain. The
folding process ultimately creates a stable structure balancing internal con-
tacts between amino acids and their occlusion to create the protein surface
and the hydrophobic core. In this work we explore a new design for applying
Generalized Simulated Annealing (GSA) on protein structure prediction,
based on previous software developed by our group. The GSA is a stochastic
search algorithm employed in energy minimization and used in global optimi-
zation problems, such as gravity models, fitting of numerical data and confor-
mation optimization of small molecules. The software deploys a new way of
updating the protein structure at each step of the simulation, a different po-
tential energy calculation function based on NAMD and parallel execution
of simulations, granting a new take on ab-initio protein structure prediction.
The design of the software also allows for the inclusion of data derived from
large scale analysis of protein structures from the PDB, as the Solvation Free
Energy, allowing us to use information already gathered by experimental
structure determinations. We present results on the 20 residue trp-cage
mini protein and mastoparan-X, a 13 amino acid peptide. Both chains fold
with RMSD of 0,2 nm and 0,1 nm respectively after 10000 GSA steps and
a molecular dinamics optimization of 1 ms for trp-cage and 200 ns for
mastoparan-X. Structure prediction softwares allow us to study protein struc-
tures that cannot be experimentally determined, by using data on chemical
bonds, non-bonded interactions and protein solvation. Once approximately
predicted, the three dimensional structure can be refined by molecular dynam-
ics simulations.
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Halogen bonds (X-bonds) result from electrostatic attractive interaction be-
tween the electropositive crown of a polarized halogen, X, and an electron-
rich Lewis base or accepting atom, A, resulting in an X_A distance closer
than the sum of traditional van der Waals radii. X-bonds have been shown to
direct protein ligand recognition and binding as well as the conformation of bi-
ological molecules. We have demonstrated via x-ray crystallography the ability
of X-bonds to direct isomeric conformation of DNA Holliday Junctions. The
stacked-X junctions can isomerize between two conformations; an X-isomer
stabilized by X-bonding at the junction crossover, or the H-isomer stabilized
by hydrogen bonding (H-bonding) at the junction crossover. The structures
of DNA Holliday junctions incorporating fluorine (F), chlorine (Cl), bromine
(Br), or iodine (I) halogenated uracil were determined by single crystal x-ray
diffraction from 1.6 to 2.2 A˚ resolution. Stabilizing X-bonds between the halo-
genated uracil and phosphate oxygen demonstrate a near linear angle of ap-
proach of the oxygen towards the halogen, consistent with current halogen
polarization and sigma hole theory. The ratio of each isomer observed in the
crystal structure was determined via occupancy refinement calculations. We
have shown that this ratio is correlated with the isomeric concentrations present
in solution and therefore an indication of stabilization energy provided by ei-
ther the X- or H-bonding, a conclusion supported by differential scanning cal-
orimetry. We observe that halogen polarization affects both the X-bondstructure and strength. The resulting structure and energy relationships of ob-
served X-bonding interactions will be employed in development and parame-
terization of an anisotropic force field to accurately model the electrostatic
and geometric treatment of halogens in current modeling programs. This will
facilitate the applications of X-bonding interactions as a tool for biomolecular
design and engineering.
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When the high-resolution structure of a protein target is available, molecular
docking experiments are commonly used for computer-aided drug discovery.
Molecular docking experiments are advantageous since they can provide the
binding mode of a molecule in a given target protein as well as the binding af-
finity. However, despite considerable efforts, accurate prediction of ligand
poses bound to a target is still challenging due to the protein’s structural flex-
ibility. Recent free energy perturbation molecular dynamics simulation (FEP/
MD) calculations have shown that the calculated binding free energies are in
good agreement with experimental data for co-crystal benchmark targets.
Here, we present an integrated methodology in which initial candidate selection
from pose decoys obtained by docking is followed by FEP/MD calculations to
improve the accuracy of near-native ligand pose prediction. Our approach is
evaluated for the small molecule a-helix mimetics inhibiting protein-protein in-
teractions such as p53-MDMX/MDM2 and BAK-MCL-1. The results demon-
strate that using the centroid models of the most populated clusters of docking
decoys is an efficient approach to select a small set of ligand conformations in
which a near-native pose may be included and applying the FEP/MD method
enhances ability in discriminating the near-native ligand conformation from
the candidates.
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Rho GTPases are conformational switches that control a wide variety of signal-
ing pathways critical for eukaryotic cell development and proliferation. They
represent attractive targets for drug design as their
aberrant function and up-regulation is associated
with many human diseases including cancer. Exten-
sive high-resolution structures and mutagenesis
studies have laid the foundation for the design of
new structure-based chemotherapeutic strategies.
We describe the application of molecular dynamics
(MD) simulations, principal component analysis,
sequence conservation analysis, fragment mapping
and ensemble small-molecule docking to provide
a complete mapping of potential small-molecule
binding pockets.
Characterized sites include novel pockets in the vi-
cinity of conformationaly responsive switch regions
as well as distal sites that appear to be allosterically linked to the nucleotide and
effecter binding regions. Intensive virtual screening and docking calculations
applied to these specific novel sites revealed promising compounds candidates
for experimental assays. Furthermore, the use of a single accelerated MD sim-
ulation, advancedMDmethod that extends the accessible time-scale of conven-
tional simulations, reveals a distribution of binding sites equivalent to the sum
of the accumulated crystal structures including transient binding sites that are
practically impossible to observe with conventional MD.
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Investigating the Mechanism of Activation and Inhibition of the Phosphate
Dependent Mitochondrial Glutaminase
Yunxing Li, Sekar Ramachandran, Richard A. Cerione.
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Glutamine metabolism often plays a crucial role in the metabolism of cancer
cells that exhibit high rates of aerobic glycolysis. The enzyme primarily re-
sponsible for the conversion of glutamine to glutamate, and ultimately the
rate of a-ketoglutarate flux into the citric acid cycle, is the mitochondrial en-
zyme glutaminase. The fully processed form of the human enzyme can be ex-
pressed in bacteria, is fully active, and in this study we use a combination of
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lographyic, and SAXS (Small Angle X-ray Scattering) to better understand
the nature of the active conformation of GAC and ultimately, how the recently
described glutaminase inhibitor 968 (J.B., Wang; Cancer Cell, 2010) interacts
with GAC and renders it inactive. Our results support a model whereby GAC
binds phosphate that results in a change in glutaminase oligomerization,
which results in active tetramers as well as higher oligomeric species. Effects
of the drug 968 on the activation/oligomerization state of glutaminase will
also be discussed.
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Structure-based design efforts on antibodies are frequently hamstrung by the
general difficulty of crystallizing antibody molecules. Computational ap-
proaches are getting more success and playing a very important role in protein
structure prediction and design. A combined platform with both computational
predication and experimental verification would have a transformative research
capability on antibody engineering. We have been developing and integrating
RosettaAntibody (homology modeling and H3 loop modeling), RosettaDock
(SnugDock and EnsembleDock) and RosettaDesign (non-canonical amino
acids design) into a systematic computational pipeline. Using the targets of
M18/Anthrax complex, which has solved crystal structure, and anti-MS2/
MS2 complex, whose antibody structure is not available, the new pipeline is
capable of building homology models for antibody from its sequence, and pre-
dicting the docked antibody-antigen structures. The correct antigen epitope can
be identified by iteratively refining the predicted candidates with experimental
verifications such as interface alanine scanning. This is followed by computa-
tional CDR designs utilizing non-canonical amino acids, which can form cova-
lent bonds with epitope residues. Along with experimental confirmations, the
incorporation of the systematical computational method was proved to signif-
icantly facilitate the epitope identification and non-canonical amino acid de-
signs. These efforts eventually substantially increased the antibody-antigen
binding affinity of the two targets.
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The envelope spike on HIV surface is a non-covalent trimer of gp120 and
gp41 dimers; with gp120 responsible for binding to the CD4 receptor and
the mandatory coreceptor, CCR5 or CXCR4. Blocking the gp120-CD4 or
gp120-coreceptor interaction can block viral entry and infection. The HNG
family of peptides (sequence RINNIXWSEAMM, X= derivatized azidopro-
line) is a promising class of dual-site entry inhibitors thought to allosterically
inhibit the binding process and trap the flexible gp120 molecule in an inac-
tive state. To date, there have been no reports on the structure of the peptide
or the peptide/gp120 complex. Here we have used Molecular Dynamics to
develop a docking model in which the peptide binds in a tripartite fashion,
preventing the formation of the bridging sheet in gp120, which is necessary
for coreceptor attachment and initiation of entry. The protein undergoes sig-
nificant induced fit conformational changes involving movement of large
loops which allows the peptide to bind tightly. Our model is consistent
with experimental observations on the peptide footprint on gp120, pointing
to a hydrophobic core underneath the bridging sheet and close to the F43
pocket as the putative binding site. Our results provide an explanation for
why the stereochemistry of the triazole moiety on the proline is important
for peptide function, in addition to explaining the inactivity of D-tryptophan
in the sequence. Furthermore, saturation transfer difference (STD) NMR ex-
periments point to the I-X-P hydrophobic center on the peptide as the central
contact point in the complex, which is consistent with the peptide pose pro-
posed in MD studies. Our model may provide a unique basis for rational de-
sign of allosteric entry inhibitors of HIV and ultimately small molecule
inhibitors of viral entry.3153-Pos Board B14
Evaluating the Potency of Small Molecules to Combat Resistance Based on
Docking Structures: An Application to the HIV Protease
Bo Ding, Nan Li, Wei Wang.
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HIV-1 protease is an important drug target for the therapy of AIDS. Up to date
nine protease drugs have been approved by the U.S. Food and Drug Adminis-
tration. However, the efficacy of these drugs is limited by the drug-resistant
mutants of the protease which can become dominant in the viral population
in several months. As it often takes years of effort and millions of dollars to de-
velop a drug, evaluating the potency of a compound to combat resistance at the
early stage of drug development would is no doubt invaluable. In this study, we
present a new procedure to predict HIV protease mutants that can be resistant to
a specific compounds based on docking structure. We exploited molecular in-
teraction energy components (MIECs) between the ligand and the protease res-
idues to characterize the docking poses. A classification method called Support
Vector Machine (SVM) is then employed to distinguish resistant from non-
resistant mutants. Most interestingly, leave-one-drug-out test showed that our
strategy can be generalized to evaluate potency of new drug lead, which sug-
gests the possibility of evaluating the potency to combat resistance for small
molecules found from virtual screening.
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Serves as a Nanovehicle to Transport and Target Bioflavonoids such as
Resveratrol
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The objective of this study is to transport resveratrol, an antioxidant and anti-
inflammatory bioflavonoid, in the plasma to targeted sites. Resveratrol is a phy-
toalexin polyphenol that is found in natural products such as grape skins, cocoa,
and is a constituent of red wine. It appears to be a potent factor as an anti-cancer
and atheroprotective agent. The ‘‘French Paradox’’ (French suffering a rela-
tively lower incidence of coronary heart disease compared to other western so-
cieties) has been attributed to the benefits of resveratrol (as a result of higher
consumption of red wine by the French). However, it is difficult to achieve ef-
fective concentrations of resveratrol in plasma via the oral tract from natural
resveratrol-rich products. Its low aqueous solubility appears to limit the use
of resveratrol as a nutraceutical agent. We propose to employ apolipoprotein
E3 (apoE3)-containing reconstituted high density lipoproteins (rHDL) for
transportation and targeted delivery of resveratrol. rHDL are water soluble li-
poprotein complexes composed of a bilayer of phospholipids surrounded by
apoE3, which bears high affinity binding sites for the cell surface localized
low density lipoprotein receptor (LDLr). The phospholipid microenvironment
of rHDL is expected to provide a centrally located lipid milieu into which re-
sveratrol may be sequestered, and shielded from modification and/or degrada-
tion. Our data indicates that resveratrol has effectively partitioned into the
hydrophobic milieu of the phospholipid bilayer of rHDL without significant al-
teration to the conformation of apoE3. Importantly, the presence of resveratrol
did not alter the LDLr binding ability of apoE3. These results indicate that
rHDL bearing the apoE3 LDLr binding domain can serve as an effective
‘‘nanovehicle’’ to transport and potentially deliver resveratrol to targeted sites
across the cell membrane.
Funded by CSUPERB and TRDRP 17RT-0165.
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Acids - Replacement of PheB24 with Cyclohexanylalanine
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Insulin replacement therapy is central to the treatment of Type 1 diabetes mel-
litus (T1DM). Clinical trials have shown that tight glycemic control in T1DM
leads to reduction in long-term diabetic complications. In an effort to better
mimic the normal post-prandial pattern of pancreatic insulin release, meal-
time insulin analogs were developed in the 1990s using standard mutagenesis.
These analogs exhibit more rapid absorption from the subcutaneous depot due
to destabilization of the zinc insulin hexamer. Unfortunately, such conventional
analogs do not achieve the rapid ‘‘on-off’’ pharmacodynamic profiles sought in
an ideal rapid-acting insulin formulation. To circumvent this limitation, we
have investigated the utility of nonstandard protein design based on unnatural
mutagenesis. Our studies have focused on residue PheB24 at the dimer inter-
face of the insulin hexamer. Investigation of the role of this aromatic side
chain by hybrid quantum-mechanical/classical molecular mechanics (QM/
cMM) suggested that substitution of the B24 aromatic ring of its saturated
